Richardson T
On both sides of the fence. 
BMA News. March 30th, 2013: 7

Richardson T
Specialist Commissioning- a clinician’s perspective.
The Endocrinologist 2013; 108, 7-8

Adaptor protein-2 sigma subunit mutations causing familial hypocalciuric hypercalcaemia type 3 (FHH3) demonstrate genotype-phenotype correlations, codon bias and dominant-negative effects. 

SA Howles, FM Hannan, VN Babinsky, A Rogers, CM Gorvin, N Rust, T Richardson, MJ McKenna, MA Nesbit, RV Thakker.
Cinacalcet for Symptomatic Hypercalcemia Caused by AP2S1 Mutations. 

J Begley, T Smith, K Barnett, P Strike, A Azim, C Spake and T Richardson
Proton pump inhibitor associated hypomagnasaemia - a cause for concern? 

MA Humayun, L Curtis, E Williams, T Richardson, AMS Brooks
Development of a specialised service for the management of diabetes secondary to pancreatic insufficiency. 
Diabetic Medicine 2016; 33, 181-181

L Curtis, H Holt, T Richardson, H Partridge
GLP-1 analogue use in patients with sub-optimally controlled type 1 diabetes or obesity improves weight and HbA1c. 
Practical Diabetes 2016; 33 (1), 13-17

Humayun MA, Richardson T, Brooks A
Fever of unknown origin in a patient initially presenting with traveller’s diarrhoea. 

A follow-up study of the prevalence of valvular heart abnormalities in hyperprolactinemic patients treated with cabergoline. 
J Clin Endocrinol Metab. 2016 Aug 29;jc20162224. [Epub ahead of print]

Humayun M, Rance C, Partridge H, Richardson T
An unusual cause of acute kidney injury. 
Partridge H, Nicholls A, Mathieu S, Perkins B
Issues in the Management of the Patient with Type 1 Diabetes on Insulin Pump Therapy in the Perioperative Period – a Primer for the Anaesthetist. British Journal Anaesthesia June 2015 (In print)


Orszag A, Falappa, Lovblom L, Partridge H, Perkins B et al.
Evaluation of a Clinical Tool to Test and Adjust the Programmed Overnight Basal Profiles for Insulin Pump Therapy: A Pilot Study.
Canadian J Diabetes. 2015 Mar 28. pii: S1499-2671 (15)00039-8

Nicholls A, Partridge H
An Introduction to Insulin Pump Therapy.
Prescriber 2014 Volume 26 (5): 11-14

Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitor Empagliflozin in Type 1 Diabetes Mellitus: Impact on Diurnal Glycemic Patterns Diabetes Technology and Therapeutics In Print.

Cherney D, Perkins B, Partridge H. et al.
Sodium Glucose Cotransport-2 Inhibition and Glycemic Control in Type 1 Diabetes Mellitus: Results of an 8-week Open Label Trial.

Kerr D, Partridge H, Knott J, Thomas P.
Hba1c 3 months after diagnosis predicts premature mortality in patients with new onset type 2 diabetes. Diabetic Med. 2011 Dec; 28(12):1520-4

Kerr D, Partridge H.
Deus Ex Machina – The Use of Technology In Diabetes Care.
Prim care Diabetes 2011 Oct; 5(3):159-65

Partridge H
Insulin Neuritis and CSII, Every silver lining has a black cloud.

A cross-sectional study of the prevalence of cardiac valvular abnormalities in hypoprolactinaemic patients treated with erfot-derived dopamine agonists.
J Clin Endocrinol Metab 2014, 99(1):90-96
doi.org/10.1210/jc.2013-2254
Keith G. McCormick, Geraldine F. Clough, Kathryn Nash, Leanne Hodson, Helen E. Moyses, Philip C. Calder, Christopher D. Byrne and on behalf of the WELCOME Study Investigators.
Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the WELCOME* study
Hepatology 2014, 60 (4): 1211-1221
DOI: 10.1002/hep.27289

Hamilton P, Nation M, Penfold S, Kerr D, Richardson T.
Reducing insulin prescription errors in hospital: more stick than carrot?
Practical Diabetes 2013; 30 (9) 370-373
DOI: 10.1002/pdi.1813

Rajendran R, Humayuon M, Richardson T.
Escherichia coli and mycotic thoracic aortic aneurysm: a case report.
Grand Rounds 2012; 12, 27-31